CGON - CIK 0001991792
CG Oncology, Inc. trades as CGON and has a market capitalization of $4.84 B, making it the #1405 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $4.04M, up 254.7% from the prior year and net income of -$161.00M. This page tracks CG Oncology, Inc. through 189 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin expanded from -23827.0% to -3985.1% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-26 |
| SCHEDULE 13G | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-08 |
| Major company event | 8-K | 2026-05-08 |
| Annual report to shareholders | ARS | 2026-04-24 |
| Proxy materials | DEFA14A | 2026-04-24 |
| Proxy statement | DEF 14A | 2026-04-24 |
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award | CG Oncology
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | CG Oncology
CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC | CG Oncology
CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates | CG Oncology
The largest companies sharing CG Oncology, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
CG Oncology, Inc. (CGON) has a market capitalization of $4.84 B as of 2026-06-11, ranking #1405 among US-listed companies.
CG Oncology, Inc. reported revenue of $4.04M for fiscal year 2025, an increase of 254.7% year over year.
In its latest fiscal year CG Oncology, Inc. reported a net loss of $161.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
CG Oncology to Present at Upcoming Investor Conferences in May | CG Oncology